{"symbol":"SZ300015","secucode":"300015.SZ","items":[{"title":"医药生物行业资金流出榜：药明康德等6股净流出资金超5000万元","summary":"沪指8月5日上涨1.47%，申万所属行业中，今日上涨的有26个，涨幅居前的行业为电子、有色金属，涨幅分别为5.66%、5.34%。医药生物行业今日上涨0.83%。跌幅居前的行业为通信、银行，跌幅分别为1.65%、1.14%。","source":null,"url":"http://stock.eastmoney.com/news/11791,202608053832635541.html","info_code":"NW202608053832635541","show_time_timestamp":1785920100000,"show_time":"2026-08-05 16:55:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608053832635541.html","url":"http://stock.eastmoney.com/news/11791,202608053832635541.html","code":"202608053832635541","infoCode":"NW202608053832635541","recordId":null,"source":null,"title":"医药生物行业资金流出榜：药明康德等6股净流出资金超5000万元","updateTime":0,"showDateTime":1785920100000,"publishDate":0,"sRatingName":null,"summary":"沪指8月5日上涨1.47%，申万所属行业中，今日上涨的有26个，涨幅居前的行业为电子、有色金属，涨幅分别为5.66%、5.34%。医药生物行业今日上涨0.83%。跌幅居前的行业为通信、银行，跌幅分别为1.65%、1.14%。"}},{"title":"爱尔眼科：公司已成立MDT多学科老视学组、布局老视门诊","summary":"8月4日，爱尔眼科在互动平台回答投资者提问时表示，随着国民眼健康意识逐步提升，潜在眼科医疗需求持续转化为现实有效需求，总体来说，相对于巨大的患者数量，老花与干眼业务目前基数不高，但未来潜力巨大，公司在各地医院持续科普患教并提供多种综合治疗方式，力求标本兼治、长治久安，为患者提供满意的医疗效果。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608043831402164.html","info_code":"NW202608043831402164","show_time_timestamp":1785846540000,"show_time":"2026-08-04 20:29:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608043831402164.html","url":"http://finance.eastmoney.com/news/1354,202608043831402164.html","code":"202608043831402164","infoCode":"NW202608043831402164","recordId":null,"source":null,"title":"爱尔眼科：公司已成立MDT多学科老视学组、布局老视门诊","updateTime":0,"showDateTime":1785846540000,"publishDate":0,"sRatingName":null,"summary":"8月4日，爱尔眼科在互动平台回答投资者提问时表示，随着国民眼健康意识逐步提升，潜在眼科医疗需求持续转化为现实有效需求，总体来说，相对于巨大的患者数量，老花与干眼业务目前基数不高，但未来潜力巨大，公司在各地医院持续科普患教并提供多种综合治疗方式，力求标本兼治、长治久安，为患者提供满意的医疗效果。"}},{"title":"爱尔眼科：公司提倡的5P近视防控理念日益普及，功能性治疗占比持续提高","summary":"8月4日，爱尔眼科在互动平台回答投资者提问时表示，公司以患者为中心，坚持“适合的才是最好的”，满足患者的多层次、个性化需求，屈光术式丰富完整，其中全光塑、全飞秒PRO、ICLV5等先进技术、术式占比稳步提升，充分体现了患者追求效果优先的基本特点，与一般消费大众追求“性价比”有所不同。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608043831400211.html","info_code":"NW202608043831400211","show_time_timestamp":1785846060000,"show_time":"2026-08-04 20:21:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608043831400211.html","url":"http://finance.eastmoney.com/news/1354,202608043831400211.html","code":"202608043831400211","infoCode":"NW202608043831400211","recordId":null,"source":null,"title":"爱尔眼科：公司提倡的5P近视防控理念日益普及，功能性治疗占比持续提高","updateTime":0,"showDateTime":1785846060000,"publishDate":0,"sRatingName":null,"summary":"8月4日，爱尔眼科在互动平台回答投资者提问时表示，公司以患者为中心，坚持“适合的才是最好的”，满足患者的多层次、个性化需求，屈光术式丰富完整，其中全光塑、全飞秒PRO、ICLV5等先进技术、术式占比稳步提升，充分体现了患者追求效果优先的基本特点，与一般消费大众追求“性价比”有所不同。"}},{"title":"爱尔眼科：公司专注眼科医疗","summary":"爱尔眼科：公司专注眼科医疗","source":null,"url":"http://finance.eastmoney.com/news/1354,202608043831376534.html","info_code":"NW202608043831376534","show_time_timestamp":1785843420000,"show_time":"2026-08-04 19:37:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608043831376534.html","url":"http://finance.eastmoney.com/news/1354,202608043831376534.html","code":"202608043831376534","infoCode":"NW202608043831376534","recordId":null,"source":null,"title":"爱尔眼科：公司专注眼科医疗","updateTime":0,"showDateTime":1785843420000,"publishDate":0,"sRatingName":null,"summary":"爱尔眼科：公司专注眼科医疗"}},{"title":"股价重返2021年底！CRO龙头距历史巅峰仅差18% 这些白马也正在归队途中","summary":"今日（8月4日），CRO板块表现活跃，截至收盘，义翘神州、双成药业、药明康德、百花医药、凯莱英等多股涨停。其中，板块龙头药明康德时隔近3个月再度涨停，股价一举创下自2021年12月以来近5年新高。注：CRO板块表现活跃（截至8月4日收盘）全天突破百亿成交，融资余额近日回升受业绩超预期及上调全年业绩指引双重提振，药明康德在横盘震荡近5周后于今日强势涨停，报收141.35元。","source":null,"url":"http://finance.eastmoney.com/news/1354,202608043831285640.html","info_code":"NW202608043831285640","show_time_timestamp":1785836007000,"show_time":"2026-08-04 17:33:27","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202608043831285640.html","url":"http://finance.eastmoney.com/news/1354,202608043831285640.html","code":"202608043831285640","infoCode":"NW202608043831285640","recordId":null,"source":null,"title":"股价重返2021年底！CRO龙头距历史巅峰仅差18% 这些白马也正在归队途中","updateTime":0,"showDateTime":1785836007000,"publishDate":0,"sRatingName":null,"summary":"今日（8月4日），CRO板块表现活跃，截至收盘，义翘神州、双成药业、药明康德、百花医药、凯莱英等多股涨停。其中，板块龙头药明康德时隔近3个月再度涨停，股价一举创下自2021年12月以来近5年新高。注：CRO板块表现活跃（截至8月4日收盘）全天突破百亿成交，融资余额近日回升受业绩超预期及上调全年业绩指引双重提振，药明康德在横盘震荡近5周后于今日强势涨停，报收141.35元。"}}]}